BNTC
Price
$7.92Alerts
Change
-$0.23 (-2.83%)
Updated
Nov 20 closing price
Capitalization
332.78M
Intraday BUY SELL Signals
KRRO
Price
$12.18Alerts
Change
-$0.01 (-0.08%)
Updated
Nov 20 closing price
Capitalization
217.2M
130 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BNTC vs KRRO

BNTC vs KRRO Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Nov 20, 2026

Which Stock Would AI Choose? Benitec Biopharma (BNTC) vs. Korro Bio (KRRO) Stock Comparison

Key Takeaways

  • Both BNTC and KRRO are clinical-stage genetic-medicine developers, but they pursue different therapeutic approaches: gene therapy versus RNA editing.
  • BNTC has generated stronger recent clinical momentum, including a 100% responder rate in its lead program and U.S. Food and Drug Administration (FDA) Fast Track designation.
  • KRRO recently lost a collaboration with Novo Nordisk, adding execution uncertainty despite new first-in-human trial progress.
  • Tickeron AI Verdict: On observable trend consistency, clinical catalysts, and relative market positioning, Tickeron's AI would currently favor BNTC over KRRO.
  • For deeper coverage, explore BNTC Major News and BNTC Today's Price Move, plus KRRO Major News and KRRO Today's Price Move.
  • To see how AI trading systems are positioning across the market, browse the Trending AI Robots page.

Introduction

This stock comparison examines two clinical-stage biotechnology companies operating in the fast-moving genetic-medicine space. BNTC, Benitec Biopharma, develops gene therapies for genetically defined diseases, while KRRO, Korro Bio, is advancing a class of medicines based on editing RNA. Both companies are pre-revenue, loss-making, and highly sensitive to clinical data and regulatory milestones, making their relative performance a useful lens for investors who follow biotech catalysts. The comparison is especially relevant to traders and investors weighing momentum, catalysts, and risk in small-cap healthcare names, where a single data readout can shift market positioning meaningfully.

BNTC Overview and Recent Performance

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines through its proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform, which combines RNA interference with gene therapy. Its lead candidate, BB-301, is being studied for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia, or difficulty swallowing.

In recent weeks, BNTC has reported notably positive clinical results: interim data from the ongoing Phase 1b/2a study showed a 100% responder rate across both low-dose and high-dose cohorts, with no treatment-related severe adverse events. The program also holds Orphan Drug and Fast Track designations from the FDA. Management has indicated plans to finalize the pivotal study design in early 2027 and begin that trial around mid-2027. These developments have supported constructive analyst sentiment, with sell-side targets rising and a prevailing "Strong Buy" consensus. The company held roughly $176 million in cash and cash equivalents as of its most recent quarter, providing a runway that supports near-term clinical execution.

KRRO Overview and Recent Performance

Korro Bio is a clinical-stage biopharmaceutical company developing genetic medicines through its OPERA RNA-editing platform, targeting both rare and more prevalent diseases. Its pipeline includes GalNAc-delivered programs for conditions such as urea cycle disorders, hepatic encephalopathy, and alpha-1 antitrypsin deficiency.

Recent activity for KRRO has been mixed. The company began dosing healthy volunteers in the Phase 1/2 ANCHOR trial of KRRO-121 and received FDA rare pediatric disease designation for that program, while also reporting more than 95% preclinical SERPINA1 mRNA editing with KRRO-111. At the same time, Novo Nordisk notified the company that it was terminating their research collaboration and license agreement, a partnership that had already been paused. This removed a potential source of milestone funding. Korro Bio ended its most recent quarter with about $124.8 million in cash, cash equivalents, and marketable securities. Analyst views remain broadly constructive but reflect wider dispersion, with price targets spanning a broad range and reflecting uncertainty around clinical and financing milestones.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a broader library of hundreds of automated strategies that trade thousands of different tickers. Only the robots best suited to current market conditions earn a place in this section, so traders can quickly focus on the systems showing the most relevant momentum. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, which lets users match a bot to their own approach. For investors seeking a data-driven angle on names like BNTC and KRRO, exploring the Trending AI Robots page offers a practical way to observe how algorithmic systems are positioning in real time.

Head-to-Head Comparison

The two companies diverge on both scientific approach and recent market positioning. BNTC is concentrated around a single advanced asset, BB-301, with a clear pivotal-trial pathway and consistently positive clinical data. KRRO operates a broader, earlier-stage platform spanning multiple indications, which offers diversification but also less clinical maturity.

On momentum, BNTC has benefited from a steady stream of favorable data and regulatory updates, while KRRO has had to balance new trial progress against the loss of its Novo Nordisk collaboration. Risk profiles also differ: BNTC carries the concentrated risk of a single asset, whereas KRRO faces platform-wide execution and financing considerations. Both names are pre-revenue and subject to the same broad sector headwinds, including cash burn and clinical-trial uncertainty, but their catalysts and near-term narratives have moved in different directions in recent weeks.

Tickeron AI Verdict

Based on observable factors such as trend consistency, catalyst density, and relative stability, Tickeron's AI would likely favor BNTC in the current environment. The company's 100% responder rate, FDA designations, and a defined path toward a pivotal trial represent a more consistent and catalyst-rich setup than KRRO, whose progress has been tempered by the loss of a key partnership. This assessment reflects a probabilistic read of recent data and market positioning rather than a definitive prediction, and it may shift as new clinical or corporate developments emerge.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
BNTC vs. KRRO commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BNTC is a Hold and KRRO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BNTC with price predictions
Nov 20, 2026

BNTC in downward trend: price may drop because broke its higher Bollinger Band on November 06, 2026

BNTC broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In 39 of the 43 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BNTC as a result. In 89 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for BNTC turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNTC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BNTC's RSI Indicator exited the oversold zone, 15 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +14.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNTC advanced for three days, in 226 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

The Aroon Indicator entered an Uptrend today. In 115 of 145 cases where BNTC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. BNTC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.880) is normal, around the industry mean (3.596). P/E Ratio (-9.735) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. BNTC's P/S Ratio (2500.000) is slightly higher than the industry average of (443.347).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNTC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for KRRO with price predictions
Nov 20, 2026

KRRO's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRRO as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for KRRO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

KRRO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 107 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.596). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (443.347).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BNTC vs KRRO: Fundamental Ratings
BNTC
KRRO
OUTLOOK RATING
1..100
7993
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
7736
P/E GROWTH RATING
1..100
2480
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRRO's Valuation (64) in the null industry is in the same range as BNTC (84) in the Biotechnology industry. This means that KRRO’s stock grew similarly to BNTC’s over the last 12 months.

KRRO's Profit vs Risk Rating (100) in the null industry is in the same range as BNTC (100) in the Biotechnology industry. This means that KRRO’s stock grew similarly to BNTC’s over the last 12 months.

BNTC's SMR Rating (97) in the Biotechnology industry is in the same range as KRRO (100) in the null industry. This means that BNTC’s stock grew similarly to KRRO’s over the last 12 months.

KRRO's Price Growth Rating (36) in the null industry is somewhat better than the same rating for BNTC (77) in the Biotechnology industry. This means that KRRO’s stock grew somewhat faster than BNTC’s over the last 12 months.

BNTC's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for KRRO (80) in the null industry. This means that BNTC’s stock grew somewhat faster than KRRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BNTCKRRO
RSI
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
83%
Bullish Trend 11 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
87%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
84%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (BNTC: $8.14 vs. KRRO: $12.19)
Brand notoriety: BNTC and KRRO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BNTC: 40% vs. KRRO: 43%
Market capitalization -- BNTC: $332.78M vs. KRRO: $217.2M
BNTC [@Biotechnology] is valued at $332.78M. KRRO’s [@Biotechnology] market capitalization is $217.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BNTC’s FA Score shows that 1 FA rating(s) are green while KRRO’s FA Score has 0 green FA rating(s).

  • BNTC’s FA Score: 1 green, 4 red.
  • KRRO’s FA Score: 0 green, 5 red.
According to our system of comparison, KRRO is a better buy in the long-term than BNTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BNTC’s TA Score shows that 4 TA indicator(s) are bullish while KRRO’s TA Score has 6 bullish TA indicator(s).

  • BNTC’s TA Score: 4 bullish, 4 bearish.
  • KRRO’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, KRRO is a better buy in the short-term than BNTC.

Price Growth

BNTC (@Biotechnology) experienced а -10.45% price change this week, while KRRO (@Biotechnology) price change was -14.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.90%. For the same industry, the average monthly price growth was -16.46%, and the average quarterly price growth was -27.70%.

Reported Earning Dates

KRRO is expected to report earnings on Mar 30, 2027.

Industries' Descriptions

@Biotechnology (-8.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BNTC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BNTC has been loosely correlated with SLDB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BNTC jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BNTC
1D Price
Change %
BNTC100%
-2.76%
SLDB - BNTC
53%
Loosely correlated
-2.95%
KYTX - BNTC
52%
Loosely correlated
-2.52%
BEAM - BNTC
51%
Loosely correlated
-0.19%
VIR - BNTC
51%
Loosely correlated
-5.41%
TSHA - BNTC
51%
Loosely correlated
-1.33%
More

KRRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRRO
1D Price
Change %
KRRO100%
-0.08%
EDIT - KRRO
49%
Loosely correlated
-4.09%
MGNX - KRRO
45%
Loosely correlated
-1.01%
RCKT - KRRO
45%
Loosely correlated
-7.58%
TRDA - KRRO
43%
Loosely correlated
-6.25%
BNTC - KRRO
40%
Loosely correlated
-2.76%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SHY81.610.23
+0.28%
iShares 1-3 Year Treasury Bond ETF (SHY)
HYBI46.80-0.26
-0.54%
NEOS Enhanced Income Credit Select ETF (HYBI)
RWEM29.55-1.23
-4.00%
Rayliant Wilshire Nxtgen Emerging Markets Equity ETF
ROCQ46.24-2.61
-5.34%
JPMorgan Nasdaq Equity Premium Yield ETF (ROCQ)
SMRF15.66-1.18
-6.99%
ALPS Nautilus SMR, Nuclear & Technology ETF (SMRF)